Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist

Molecular Endocrinology

Volumn 16, Issue 4, 2002, Pages 736-746

  Vlaeminck Guillem, Virginie ^a   Ho, Su Chin ^b   Rodien, Patrice ^c   Vassart, Gilbert ^a   Costagliola, Sabine ^d  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYCLIC AMP; RHODOPSIN; THYROTROPIN RECEPTOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CONFORMATIONAL TRANSITION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; RECEPTOR INTRINSIC ACTIVITY; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALIA; BOVINAE;

EID: 0036214718     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.16.4.736     Document Type: Article

References (57)

1. Molecular tinkering of G protein-coupled receptors: An evolutionary success
2. Physiological regulation of G protein-linked signaling
3. Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors
4. A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model
5. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors
6. Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F
7. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin
8. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism
9. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas
10. Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness
11. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty
12. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia
13. Constitutively active mutants of the α2-adrenergic receptor
14. Constitutive activation of the α1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation
15. Characterization of the binding domain of the β-adrenergic receptor with the fluorescent antagonist carazolol. Evidence for a buried ligand binding site
16. Biophysical and genetic analysis of the ligand-binding site of the β-adrenoceptor
17. Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor
18. Crystal structure of human chorionic gonadotropin
19. Three-dimensional structure of human follicle-stimulating hormone
20. Molecular cloning of the thyrotropin receptor
21. The testicular receptor for follicle stimulating hormone: Structure and functional expression of cloned cDNA
22. Lutropin-choriogonadotropin receptor: An unusual member of the G protein-coupled receptor family
23. Extracellular domain chimeras of the TSH and LH/CG receptors reveal the mid-region (amino acids 171-260) to play a vital role in high affinity TSH binding
24. Thyrotropin-luteinizing hormone/chorionic gonadotropin receptor extracellular domain chimeras as probes for thyrotropin receptor function
25. Production of bioactive amino-terminal domain of the thyrotropin receptor via insertion in the plasma membrane by a glycosylphosphatidylinositol anchor
26. Production of the thyrotrophin receptor extracellular domain as a glycosylphosphatidylinositol-anchored membrane protein and its interaction with thyrotrophin and autoantibodies
27. Soluble ecto-domain mutant of thyrotropin (TSH) receptor incapable of binding TSH neutralizes the action of thyroid-stimulating antibodies from Graves' patients
28. Human choriogonadotropin binds to a lutropin receptor with essentially no N-terminal extension and stimulates cAMP synthesis
29. Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors
30. TSH receptor binding and thyroid stimulation by sera from patients with Graves' disease
31. Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: Evidence for binding of autoantibodies
32. Constitutive activation of the TSH receptor by spontaneous mutations affecting the N-terminal extracellular domain
33. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gsα genes as a cause of toxic thyroid adenomas
34. Effects of mutations involving the highly conserved S281HCC motif in the extracellular domain of the thyrotropin (TSH) receptor on TSH binding and constitutive activity
35. Specific activation of the thyrotropin receptor by trypsin
36. The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: Implications for hormone-receptor interaction and antagonist design
37. Identification of ligands for olfactory receptors by functional expression of a receptor library
38. Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor
39. Sequential cleavage and excision of a segment of the thyrotropin receptor ectodomain
40. Two-subunit structure of the human thyrotropin receptor
41. Evidence that the thyrotropin receptor ectodomain contains not one, but two, cleavage sites
42. Integraged methods for the construction of three-dimentional models and computational probing of structure-function relations in G protein-coupled receptors
43. A conserved ASN in TM7 is a on/off switch in the activation of the TSH receptor
44. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility
45. Constitutive activity of glucagon receptor mutants
46. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281→isoleucine) in the extracellular domain of the thyrotropin receptor
47. Activation of the luteinizing hormone receptor following substitution of Ser-277 with selective hydrophobic residues in the ectodomain hinge region
48. Structure. Rhodopsin sees the light
49. Observations of light-induced structural changes of retinal within rhodopsin
50. Crystal structure of rhodopsin: A G protein-coupled receptor
51. The thyrotropin (TSH) receptor: Interaction with TSH and autoantibodies
52. Immunoglobulins from Graves' disease patients interact with different sites on TSH receptor/LH-CG receptor chimeras than either TSH or immunoglobulins from idiopathic myxedema patients
53. Anti-rhodopsin monoclonal antibodies of defined specificity: Characterization and application
54. Site-specific mutagenesis by using an accurate recombinant polymerase chain reaction method
55. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters
56. High level transient expression of a chloramphenicol acetyl transferase gene by DEAE-dextran mediated DNA transfection coupled with a dimethyl sulfoxide or glycerol shock treatment
57. Radioimmunoassay of cyclic AMP and cyclic GMP